Aspergillus terreus strain improvement for enhanced lovastatin production

Autores
Babot, Jaime Daniel; Caro, Florencia Cecilia; Delgado, Osvaldo Daniel; Fariña, Julia Ines
Año de publicación
2015
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Cholesterol plays a vital role in body metabolism and membrane transport, and acts as precursor for the synthesis of several key biomolecules. Nevertheless, changes in cholesterol level lead to cardiovascular disorders, like atherosclerosis and hypercholesterolemia, which are currently the main causes of death. This is why controlling cholesterol by inhibition of its biosynthesis is a promising approach. Cholesterol is synthetized from acetyl-CoA through a complex pathway, where the rate-limiting step is the conversion of HMG-CoA to mevalonate, catalyzed by HMG-CoA reductase. This key enzyme is selectively and competitively inhibited by lovastatin, a fungal secondary metabolite used as a hypocholesterolemic which can therefore reduce the risk of cardiovascular diseases. Lovastatin production is normally carried out using selected Aspergillus terreus strains, however industrial process yields may be improved by strain manipulation. Accordingly, the aim of this work was to develop a lovastatin-hyperproducing A. terreus strain. To this end, 107-spores/mL suspensions of lovastatin-producer A. terreus MEC were exposed to UV radiation for different times ranging from 5 to 15 min. Spores were kept in the dark for 30 min, plated onto PDA plates and incubated at 25°C for 48 h. Isolated colonies were transferred to an optimized lovastatin production medium (SQop) containing cheese-whey as substrate and incubated at 25°C for 14 days. Lovastatin was extracted from fungal colonies by using ethyl acetate and converted to its β-hydroxyacid form by alkaline hydrolysis. Organic extracts were preliminary analyzed by TLC, and spot intensities were quantified with ImageJ software. The amount of lovastatin was quantified by RP-HPLC. In a second stage, selected lovastatin hyperproducing mutants were subjected to another mutation cycle and further evaluated. The first obtained 164 putative mutants were comparatively analyzed against the wild-type (WT) A. terreus MEC strain and, according to TLC results, 28 mutants produced 20% or less than it, whilst 20 out of the 164 produced 20% (or higher) more lovastatin than WT. These results, as confronted to the HPLC analyses, confirmed 6 mutant strains with 20%-lower production than WT strain, while only one showed a hyperproducing phenotype. This latter mutant, named C10´-27, produced 168% more (2.35 g/L) lovastatin than WT strain. After a second mutation cycle of A. terreus C10´-27, 157 putative mutants were analyzed. Lovastatin production, as witnessed by RP-HPLC, increased by 20% or higher than the one for C10´-27 for 5 of the obtained mutants. The highest lovastatin titer was achieved by mutant A. terreus S12,5´-9 with a 40% increase over the already improved production of A. terreus C10´-27. These results pave the way to a more efficient lovastatin production by using the selected mutant and may additionally open new perspectives for reducing its production costs.
Fil: Babot, Jaime Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina
Fil: Caro, Florencia Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina
Fil: Delgado, Osvaldo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia de Catamarca. Universidad Nacional de Catamarca. Centro de Investigaciones y Transferencia de Catamarca; Argentina. Universidad Nacional de Catamarca. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Fariña, Julia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina. Universidad Nacional de Catamarca. Facultad de Ciencias Exactas y Naturales; Argentina
XI Congreso Argentino de Microbiología General
Córdoba
Argentina
Sociedad Argentina de Microbiología General
Materia
LOVASTATIN
ENHANCED PRODUCTION
ASPERGILLUS TERREUS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/221462

id CONICETDig_8094a68afe87b7af832078b25c205659
oai_identifier_str oai:ri.conicet.gov.ar:11336/221462
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Aspergillus terreus strain improvement for enhanced lovastatin productionBabot, Jaime DanielCaro, Florencia CeciliaDelgado, Osvaldo DanielFariña, Julia InesLOVASTATINENHANCED PRODUCTIONASPERGILLUS TERREUShttps://purl.org/becyt/ford/2.9https://purl.org/becyt/ford/2Cholesterol plays a vital role in body metabolism and membrane transport, and acts as precursor for the synthesis of several key biomolecules. Nevertheless, changes in cholesterol level lead to cardiovascular disorders, like atherosclerosis and hypercholesterolemia, which are currently the main causes of death. This is why controlling cholesterol by inhibition of its biosynthesis is a promising approach. Cholesterol is synthetized from acetyl-CoA through a complex pathway, where the rate-limiting step is the conversion of HMG-CoA to mevalonate, catalyzed by HMG-CoA reductase. This key enzyme is selectively and competitively inhibited by lovastatin, a fungal secondary metabolite used as a hypocholesterolemic which can therefore reduce the risk of cardiovascular diseases. Lovastatin production is normally carried out using selected Aspergillus terreus strains, however industrial process yields may be improved by strain manipulation. Accordingly, the aim of this work was to develop a lovastatin-hyperproducing A. terreus strain. To this end, 107-spores/mL suspensions of lovastatin-producer A. terreus MEC were exposed to UV radiation for different times ranging from 5 to 15 min. Spores were kept in the dark for 30 min, plated onto PDA plates and incubated at 25°C for 48 h. Isolated colonies were transferred to an optimized lovastatin production medium (SQop) containing cheese-whey as substrate and incubated at 25°C for 14 days. Lovastatin was extracted from fungal colonies by using ethyl acetate and converted to its β-hydroxyacid form by alkaline hydrolysis. Organic extracts were preliminary analyzed by TLC, and spot intensities were quantified with ImageJ software. The amount of lovastatin was quantified by RP-HPLC. In a second stage, selected lovastatin hyperproducing mutants were subjected to another mutation cycle and further evaluated. The first obtained 164 putative mutants were comparatively analyzed against the wild-type (WT) A. terreus MEC strain and, according to TLC results, 28 mutants produced 20% or less than it, whilst 20 out of the 164 produced 20% (or higher) more lovastatin than WT. These results, as confronted to the HPLC analyses, confirmed 6 mutant strains with 20%-lower production than WT strain, while only one showed a hyperproducing phenotype. This latter mutant, named C10´-27, produced 168% more (2.35 g/L) lovastatin than WT strain. After a second mutation cycle of A. terreus C10´-27, 157 putative mutants were analyzed. Lovastatin production, as witnessed by RP-HPLC, increased by 20% or higher than the one for C10´-27 for 5 of the obtained mutants. The highest lovastatin titer was achieved by mutant A. terreus S12,5´-9 with a 40% increase over the already improved production of A. terreus C10´-27. These results pave the way to a more efficient lovastatin production by using the selected mutant and may additionally open new perspectives for reducing its production costs.Fil: Babot, Jaime Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; ArgentinaFil: Caro, Florencia Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; ArgentinaFil: Delgado, Osvaldo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia de Catamarca. Universidad Nacional de Catamarca. Centro de Investigaciones y Transferencia de Catamarca; Argentina. Universidad Nacional de Catamarca. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Fariña, Julia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina. Universidad Nacional de Catamarca. Facultad de Ciencias Exactas y Naturales; ArgentinaXI Congreso Argentino de Microbiología GeneralCórdobaArgentinaSociedad Argentina de Microbiología GeneralSociedad Argentina de Microbiología General2015info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectCongresoBookhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/221462Aspergillus terreus strain improvement for enhanced lovastatin production; XI Congreso Argentino de Microbiología General; Córdoba; Argentina; 2015; 102-103CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://samige.org.ar/wp-content/uploads/2022/10/Libro-samige-2013.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:53:22Zoai:ri.conicet.gov.ar:11336/221462instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:53:22.565CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Aspergillus terreus strain improvement for enhanced lovastatin production
title Aspergillus terreus strain improvement for enhanced lovastatin production
spellingShingle Aspergillus terreus strain improvement for enhanced lovastatin production
Babot, Jaime Daniel
LOVASTATIN
ENHANCED PRODUCTION
ASPERGILLUS TERREUS
title_short Aspergillus terreus strain improvement for enhanced lovastatin production
title_full Aspergillus terreus strain improvement for enhanced lovastatin production
title_fullStr Aspergillus terreus strain improvement for enhanced lovastatin production
title_full_unstemmed Aspergillus terreus strain improvement for enhanced lovastatin production
title_sort Aspergillus terreus strain improvement for enhanced lovastatin production
dc.creator.none.fl_str_mv Babot, Jaime Daniel
Caro, Florencia Cecilia
Delgado, Osvaldo Daniel
Fariña, Julia Ines
author Babot, Jaime Daniel
author_facet Babot, Jaime Daniel
Caro, Florencia Cecilia
Delgado, Osvaldo Daniel
Fariña, Julia Ines
author_role author
author2 Caro, Florencia Cecilia
Delgado, Osvaldo Daniel
Fariña, Julia Ines
author2_role author
author
author
dc.subject.none.fl_str_mv LOVASTATIN
ENHANCED PRODUCTION
ASPERGILLUS TERREUS
topic LOVASTATIN
ENHANCED PRODUCTION
ASPERGILLUS TERREUS
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.9
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Cholesterol plays a vital role in body metabolism and membrane transport, and acts as precursor for the synthesis of several key biomolecules. Nevertheless, changes in cholesterol level lead to cardiovascular disorders, like atherosclerosis and hypercholesterolemia, which are currently the main causes of death. This is why controlling cholesterol by inhibition of its biosynthesis is a promising approach. Cholesterol is synthetized from acetyl-CoA through a complex pathway, where the rate-limiting step is the conversion of HMG-CoA to mevalonate, catalyzed by HMG-CoA reductase. This key enzyme is selectively and competitively inhibited by lovastatin, a fungal secondary metabolite used as a hypocholesterolemic which can therefore reduce the risk of cardiovascular diseases. Lovastatin production is normally carried out using selected Aspergillus terreus strains, however industrial process yields may be improved by strain manipulation. Accordingly, the aim of this work was to develop a lovastatin-hyperproducing A. terreus strain. To this end, 107-spores/mL suspensions of lovastatin-producer A. terreus MEC were exposed to UV radiation for different times ranging from 5 to 15 min. Spores were kept in the dark for 30 min, plated onto PDA plates and incubated at 25°C for 48 h. Isolated colonies were transferred to an optimized lovastatin production medium (SQop) containing cheese-whey as substrate and incubated at 25°C for 14 days. Lovastatin was extracted from fungal colonies by using ethyl acetate and converted to its β-hydroxyacid form by alkaline hydrolysis. Organic extracts were preliminary analyzed by TLC, and spot intensities were quantified with ImageJ software. The amount of lovastatin was quantified by RP-HPLC. In a second stage, selected lovastatin hyperproducing mutants were subjected to another mutation cycle and further evaluated. The first obtained 164 putative mutants were comparatively analyzed against the wild-type (WT) A. terreus MEC strain and, according to TLC results, 28 mutants produced 20% or less than it, whilst 20 out of the 164 produced 20% (or higher) more lovastatin than WT. These results, as confronted to the HPLC analyses, confirmed 6 mutant strains with 20%-lower production than WT strain, while only one showed a hyperproducing phenotype. This latter mutant, named C10´-27, produced 168% more (2.35 g/L) lovastatin than WT strain. After a second mutation cycle of A. terreus C10´-27, 157 putative mutants were analyzed. Lovastatin production, as witnessed by RP-HPLC, increased by 20% or higher than the one for C10´-27 for 5 of the obtained mutants. The highest lovastatin titer was achieved by mutant A. terreus S12,5´-9 with a 40% increase over the already improved production of A. terreus C10´-27. These results pave the way to a more efficient lovastatin production by using the selected mutant and may additionally open new perspectives for reducing its production costs.
Fil: Babot, Jaime Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina
Fil: Caro, Florencia Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina
Fil: Delgado, Osvaldo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Investigaciones y Transferencia de Catamarca. Universidad Nacional de Catamarca. Centro de Investigaciones y Transferencia de Catamarca; Argentina. Universidad Nacional de Catamarca. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Fariña, Julia Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Planta Piloto de Procesos Industriales Microbiológicos; Argentina. Universidad Nacional de Catamarca. Facultad de Ciencias Exactas y Naturales; Argentina
XI Congreso Argentino de Microbiología General
Córdoba
Argentina
Sociedad Argentina de Microbiología General
description Cholesterol plays a vital role in body metabolism and membrane transport, and acts as precursor for the synthesis of several key biomolecules. Nevertheless, changes in cholesterol level lead to cardiovascular disorders, like atherosclerosis and hypercholesterolemia, which are currently the main causes of death. This is why controlling cholesterol by inhibition of its biosynthesis is a promising approach. Cholesterol is synthetized from acetyl-CoA through a complex pathway, where the rate-limiting step is the conversion of HMG-CoA to mevalonate, catalyzed by HMG-CoA reductase. This key enzyme is selectively and competitively inhibited by lovastatin, a fungal secondary metabolite used as a hypocholesterolemic which can therefore reduce the risk of cardiovascular diseases. Lovastatin production is normally carried out using selected Aspergillus terreus strains, however industrial process yields may be improved by strain manipulation. Accordingly, the aim of this work was to develop a lovastatin-hyperproducing A. terreus strain. To this end, 107-spores/mL suspensions of lovastatin-producer A. terreus MEC were exposed to UV radiation for different times ranging from 5 to 15 min. Spores were kept in the dark for 30 min, plated onto PDA plates and incubated at 25°C for 48 h. Isolated colonies were transferred to an optimized lovastatin production medium (SQop) containing cheese-whey as substrate and incubated at 25°C for 14 days. Lovastatin was extracted from fungal colonies by using ethyl acetate and converted to its β-hydroxyacid form by alkaline hydrolysis. Organic extracts were preliminary analyzed by TLC, and spot intensities were quantified with ImageJ software. The amount of lovastatin was quantified by RP-HPLC. In a second stage, selected lovastatin hyperproducing mutants were subjected to another mutation cycle and further evaluated. The first obtained 164 putative mutants were comparatively analyzed against the wild-type (WT) A. terreus MEC strain and, according to TLC results, 28 mutants produced 20% or less than it, whilst 20 out of the 164 produced 20% (or higher) more lovastatin than WT. These results, as confronted to the HPLC analyses, confirmed 6 mutant strains with 20%-lower production than WT strain, while only one showed a hyperproducing phenotype. This latter mutant, named C10´-27, produced 168% more (2.35 g/L) lovastatin than WT strain. After a second mutation cycle of A. terreus C10´-27, 157 putative mutants were analyzed. Lovastatin production, as witnessed by RP-HPLC, increased by 20% or higher than the one for C10´-27 for 5 of the obtained mutants. The highest lovastatin titer was achieved by mutant A. terreus S12,5´-9 with a 40% increase over the already improved production of A. terreus C10´-27. These results pave the way to a more efficient lovastatin production by using the selected mutant and may additionally open new perspectives for reducing its production costs.
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Congreso
Book
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/221462
Aspergillus terreus strain improvement for enhanced lovastatin production; XI Congreso Argentino de Microbiología General; Córdoba; Argentina; 2015; 102-103
CONICET Digital
CONICET
url http://hdl.handle.net/11336/221462
identifier_str_mv Aspergillus terreus strain improvement for enhanced lovastatin production; XI Congreso Argentino de Microbiología General; Córdoba; Argentina; 2015; 102-103
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://samige.org.ar/wp-content/uploads/2022/10/Libro-samige-2013.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Sociedad Argentina de Microbiología General
publisher.none.fl_str_mv Sociedad Argentina de Microbiología General
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269220243505152
score 13.13397